loading...| Preferred Name |
Panitumumab |
|
| Synonyms |
PANITUMUMAB ABX-EGF Monoclonal Antibody MoAb E7.6.3 MoAb ABX-EGF Monoclonal Antibody ABX-EGF Human IgG2K Monoclonal Antibody ABX-EGF, Clone E7.6.3 Panitumumab Monoclonal Antibody E7.6.3 panitumumab ABX-EGF E7.6.3 Vectibix |
|
| Definitions |
A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1857 |
|
| Accepted_Therapeutic_Use_For |
Advanced Stage Colorectal Cancer |
|
| ALT_DEFINITION |
A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. ABX-EGF binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth. |
|
| CAS_Registry |
339177-26-3 |
|
| code |
C1857 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI) |
|
| Display_Name |
Panitumumab |
|
| FDA_UNII_Code |
6A901E312A |
|
| FULL_SYN |
PANITUMUMAB ABX-EGF Monoclonal Antibody MoAb E7.6.3 MoAb ABX-EGF Monoclonal Antibody ABX-EGF Human IgG2K Monoclonal Antibody ABX-EGF, Clone E7.6.3 Panitumumab Monoclonal Antibody E7.6.3 panitumumab ABX-EGF E7.6.3 Vectibix |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Panitumumab |
|
| Legacy Concept Name |
Monoclonal_Antibody_ABX-EGF |
|
| Maps_To |
Panitumumab |
|
| NCI_Drug_Dictionary_ID |
37857 |
|
| PDQ_Closed_Trial_Search_ID |
37857 |
|
| PDQ_Open_Trial_Search_ID |
37857 |
|
| Preferred_Name |
Panitumumab |
|
| prefixIRI |
Thesaurus:C1857 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C1513448 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742 |